Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Gaviscon Advance Peppermint Flavour Oral Suspension
⚠ This medicine appears to have been discontinued
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Sodium alginate, Potassium bicarbonate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
How to take it
this medicine. Check that the cap seal is unbroken before first using this product. Shake well before use. Adults including the elderly and children 12 years and over: 5-10 ml (one to two 5ml spoonfuls} after meals and at bedtime. Children under 12 years: Should only be taken on medical
–ae
| Antagonists. | 2. Before taking this medicine.
eee
eee
Ke Ke Kee
| cooking/table salt) in each 5 mi. This is equivalent to 2.9% of the recommended maximum daily dietary intake of sodium for an | adult.
| The maximum recommended daily dose of this medicinal | product contains 462.8 mg sodium (found in table salt). This is equivalent to 23.14% of the adult recommended maximum daily
—–
——-G
—-
—-r— KH
| leaflet. You can also report side effects directly via the Yellow Card Scheme at: "http:/Awww.mhra.gov.uk/yellowcard" or search | for MHRA Yellow Card in the Google Play or Apple App Store. By | reporting side effects, you can help provide more information on | the safety of this medicine. 5, How to store this medicine. : Do not use this product after the expiry date (EXP: month/year) | Shown. Use within 6 months of opening. Keep out of the sight | and reach of children. | Do not refrigerate. | Medicines should not be disposed of via wastewater or | household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to | protect the environment. |
daily basis for a prolonged period of time, especially if you have been advised to have a low salt diet. This medicine contains 1.0 mmol (39.06 mg) potassium per 5 ml. To be taken into consideration by patients with reduced kidney function or patients ona controlled potassium diet. Taking other medicines: Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without prescription. Wait at least 2 hours between taking this medicine and other medicines such as tetracyclines, fluoroquinolones (types of antibiotics), iron salts, thyroid hormones, chloroquine (a medication used to prevent malaria), bisphosphonates (a medication used to treat osteoporosis) and estramustine (a medication to treat prostate cancer). Pregnancy and breast-feeding: You can take this product if you are pregnant or breast-feeding.
pe
- ee
–
He ee
ee
ee
Ke Ke
ee
ee
Ke
Ke
Ke ee
Ke
Ke
Ke eK
Each 10 ml of oral suspension contains 1000 mg sodium alginate and 200 mg potassium hydrogen carbonate as the active ingredients. The other ingredients are calcium carbonate, carbomer, methyl (E218) and propyl (E216) parahydroxybenzoates, sodium saccharin, sodium hydroxide, peppermint flavour and purified water. This product does not contain sugar or gluten. Gaviscon Advance is available in bottles of 80 ml, 100 ml, 125 ml, 140 ml, 150 ml, 180 ml, 200 ml, 250 ml, 300 ml, 400 ml, 500 ml, 560 ml, or 600 ml. Not all pack sizes may be marketed. Manufacturer and Product Licence Holder: Reckitt Benckiser Healthcare (UK) Limited, Hull, HU8 7DS. UK Distributor: Forum Health Products. Date of preparation: June 2024 Gaviscon is a trade mark of the Reckitt group.
Ke
Ee
Possible side effects
. Like all medicines, this medicine can cause side effects, although not everybody gets them. Very rarely (less than 1 in 10,000 patients) there is a chance of an allergic reaction to the ingredients. Symptoms of this may include skin rash, itching, difficulty breathing, dizziness or swelling of the face, lips, tongue or throat. Uncommonly reported side-effects are diarrhoea, nausea and vomiting (less than 1 in 100 people). If you experience these or any other side effects stop taking the product and consult your doctor immediately.
=-
Important information about some of the ingredients of Gaviscon Advance: This product contains methyl (E218) and propyl (E216) para-hydroxybenzoates which may cause allergic reactions (possibly delayed). Driving and using machines: This medicine has no influence on the ability to drive and use machines.
How to store it
this medicine. 6. Further information.
: stomach acid such as Proton Pump Inhibitors (PPIs) or H2
1. What is this medicine and what is it used for? Gaviscon Advance belongs to a group of medicines called 'reflux suppressants', This product forms a protective layer that floats on top of the stomach contents. This layer prevents reflux and keeps the stomach contents away from the lining of the food pipe to relieve the symptoms of heartburn and acid indigestion. It can also be used to relieve the symptoms of conditions such as hiatus hernia (protrusion of muscle through a muscle wall), reflux oesophagitis (inflamed foodpipe) and symptoms of hoarseness and other voice disorders, sore throat and cough associated with reflux.
; Do not take Gaviscon Advance: | – If you know you are allergic (hypersensitive) to any of the | ingredients in this product (see 'Further Information' for a full list | of ingredients). | Take special care with Gaviscon Advance: | This medicine contains 57.85 mg sodium (main component of
limited as much as possible.
dose next time, just carry on taking as before. If you take too much of this product you may feel bloated and experience some abdominal discomfort. It is unlikely to cause you any harm, but please consult your doctor or pharmacist if this doesn't go away. If symptoms persist after 7 days consult your doctor.
Frequently asked questions about Gaviscon Advance Peppermint Flavour Oral Suspension
How do I take Gaviscon Advance Peppermint Flavour Oral Suspension?
Gaviscon Advance Peppermint Flavour Oral Suspension comes as oral solution. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
What is the active substance in Gaviscon Advance Peppermint Flavour Oral Suspension?
The active substance in Gaviscon Advance Peppermint Flavour Oral Suspension is sodium alginate, potassium bicarbonate.
Are there equivalent medicines to Gaviscon Advance Peppermint Flavour Oral Suspension?
Medicines with the same active substance, strength and form include: Gaviscon Advance Aniseed Oral Suspension. They are interchangeable only if your prescriber or pharmacist says so.
Where does this information come from?
This leaflet reproduces the patient information leaflet approved for Gaviscon Advance Peppermint Flavour Oral Suspension, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Can I get Gaviscon Advance Peppermint Flavour Oral Suspension without a prescription?
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
About this leaflet
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
- Source: electronic medicines compendium (emc), Datapharm
- Active substance: sodium alginate, potassium bicarbonate
- Official document: view the original leaflet on emc →
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
4.1. Therapeutic indications
Treatment of symptoms resulting from the reflux of acid, bile and pepsin into the oesophagus such as acid regurgitation, heartburn, indigestion (occurring due to the reflux of stomach contents), for instance, after gastric surgery, as a result of hiatus hernia, during pregnancy, accompanying reflux oesophagitis, including symptoms of laryngopharyngeal reflux such as hoarseness and other voice disorders, sore throats and cough. It can also be used to treat the symptoms of gastro-oesophageal reflux during concomitant treatment with or following withdrawal of acid suppressing therapy.
4.2. Posology and method of administration
Adults and children 12 years and over: 5-10 ml after meals and at bedtime (one to two 5 ml measuring spoons).
Children under 12 years: Should be given only on medical advice.
Elderly: No dose modification is required for this age group.
Hepatic Impairment: No dose modification necessary.
Renal Insufficiency: Caution if highly restricted salt diet is necessary (see section 4.4).
4.3. Contraindications
The medicinal product is contraindicated in patients with known or suspected hypersensitivity to the active substances or to any of the excipients listed in section 6.1, including methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) (see section 4.4).
4.4. Special warnings and precautions for use
If symptoms do not improve after 7 days, the clinical situation should be reviewed.
This medicinal product contains 57.85 mg sodium per 5 ml, equivalent to 2.9 % of the WHO recommended maximum daily intake for sodium.
The maximum daily dose of this product is equivalent to 23.14 % of the WHO recommended maximum daily intake for sodium.
This product is considered high in sodium. This should be particularly taken into account for those on a low salt diet (e.g. in some cases of congestive heart failure and renal impairment).
Potassium: This medicine contains 1.0 mmol (39.06 mg) Potassium per 5 ml. To be taken into consideration by patients with reduced kidney function or patients on a controlled potassium diet.
Each 10 ml contains 200 mg (2.0 mmol) of calcium carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi.
This medicinal product contains Methyl hydroxybenzoate and Propyl hydroxybenzoate, which may cause allergic reactions (possibly delayed).
4.5. Interaction with other medicinal products and other forms of interaction
A time-interval of 2 hours should be considered between Gaviscon intake and the administration of other medicinal products, especially tetracyclines, fluoroquinolones, iron salts, thyroid hormones, chloroquine, bisphosphonates, and estramustine.
4.6. Fertility, pregnancy and lactation
Pregnancy:
Clinical studies in more than 500 pregnant women as well as a large amount of data from post-marketing experience indicate no malformative nor foeto/neonatal toxicity of the active substances. Gaviscon can be used during pregnancy, if clinically needed.
Breast feeding:
No known effect on breast fed infants. Gaviscon can be used during breast feeding.
Fertility:
No known effect on human fertility.
4.7. Effects on ability to drive and use machines
Not relevant.
4.8. Undesirable effects
Adverse reactions have been ranked under headings of frequency using the following convention: very common (1/10), common (1/100 and <1/10), uncommon (1/1000 and <1/100), rare (1/10,000 and <1/1000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).
System Organ Class
Frequency
Adverse Event
Gastrointestinal Disorders
Uncommon
Diarrhoea, nausea, vomiting.
Immune System Disorders
Very rare
Anaphylactic and anaphylactoid reactions. Hypersensitivity reactions such as urticaria.
Respiratory, Thoracic and Mediastinal Disorders
Very rare
Respiratory effects such as bronchospasm.
Reporting of Suspected Adverse Reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9. Overdose
Symptoms
Symptoms are likely to be minor; some abdominal discomfort may be experienced.
Management
In the event of overdose, symptomatic treatment should be given.
💬 Ask about this leaflet
Ask anything about Gaviscon Advance Peppermint Flavour Oral Suspension. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.